{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T14:56:02Z","timestamp":1791039362004,"version":"4.1.0"},"reference-count":110,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Finnish Glycoscience Graduate School"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.phrs.2013.12.001","type":"journal-article","created":{"date-parts":[[2013,12,16]],"date-time":"2013-12-16T23:30:58Z","timestamp":1387236658000},"page":"52-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Targeting opioid receptors with pharmacological chaperones"],"prefix":"10.1016","volume":"83","author":[{"given":"Ulla E.","family":"Pet\u00e4j\u00e4-Repo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarkko J.","family":"Lackman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2013.12.001_bib0005","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1152\/physrev.00050.2006","article-title":"In and out of the ER: protein folding, quality control, degradation, and related human diseases","volume":"87","author":"Hebert","year":"2007","journal-title":"Physiol Rev"},{"key":"10.1016\/j.phrs.2013.12.001_bib0010","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1146\/annurev-biochem-062209-093836","article-title":"Protein folding and modification in the mammalian endoplasmic reticulum","volume":"80","author":"Braakman","year":"2011","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.phrs.2013.12.001_bib0015","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1126\/science.1209235","article-title":"Road to ruin: targeting proteins for degradation in the endoplasmic reticulum","volume":"334","author":"Smith","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.phrs.2013.12.001_bib0020","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.cell.2012.11.012","article-title":"Cleaning up: ER-associated degradation to the rescue","volume":"151","author":"Brodsky","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2013.12.001_bib0025","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/35008096","article-title":"Rapid degradation of a large fraction of newly synthesized proteins by proteasomes","volume":"404","author":"Schubert","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2013.12.001_bib0030","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.pharmthera.2006.02.008","article-title":"Inactivating mutations of G protein-coupled receptors and diseases: structure\u2013function insights and therapeutic implications","volume":"111","author":"Tao","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.phrs.2013.12.001_bib0035","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/nrendo.2011.20","article-title":"G protein-coupled receptors: mutations and endocrine diseases","volume":"7","author":"Vassart","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.phrs.2013.12.001_bib0040","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.addr.2007.06.002","article-title":"Visiting the ER: the endoplasmic reticulum as a target for therapeutics in traffic related diseases","volume":"59","author":"Aridor","year":"2007","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.phrs.2013.12.001_bib0045","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1126\/science.1141448","article-title":"Adapting proteostasis for disease intervention","volume":"319","author":"Balch","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.phrs.2013.12.001_bib0050","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ceb.2010.11.002","article-title":"Chemical and\/or biological therapeutic strategies to ameliorate protein misfolding diseases","volume":"23","author":"Ong","year":"2011","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.phrs.2013.12.001_bib0055","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0165-6147(00)01575-3","article-title":"Pharmacological chaperones: a new twist on receptor folding","volume":"21","author":"Morello","year":"2000","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.phrs.2013.12.001_bib0060","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1600-0854.2004.00232.x","article-title":"Pharmacologic rescue of conformationally defective proteins: implications for the treatment of human disease","volume":"5","author":"Ulloa-Aguirre","year":"2004","journal-title":"Traffic"},{"key":"10.1016\/j.phrs.2013.12.001_bib0065","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1600-0854.2004.00231.x","article-title":"A cure for traffic jams: small molecule chaperones in the endoplasmic reticulum","volume":"5","author":"R\u00f6misch","year":"2004","journal-title":"Traffic"},{"key":"10.1016\/j.phrs.2013.12.001_bib0070","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.tem.2004.05.003","article-title":"Pharmacological chaperones: potential treatment for conformational diseases","volume":"15","author":"Bernier","year":"2004","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.phrs.2013.12.001_bib0075","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1210\/me.2004-0080","article-title":"Functional rescue of the constitutively internalized V2 Vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059","volume":"18","author":"Bernier","year":"2004","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.phrs.2013.12.001_bib0080","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1172\/JCI8688","article-title":"Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants","volume":"105","author":"Morello","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.phrs.2013.12.001_bib0085","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1093\/emboj\/21.7.1628","article-title":"Ligands act as pharmacological chaperones and increase the efficiency of \u03b4 opioid receptor maturation","volume":"21","author":"Pet\u00e4j\u00e4-Repo","year":"2002","journal-title":"EMBO J"},{"key":"10.1016\/j.phrs.2013.12.001_bib0090","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1210\/jcem.87.7.8582","article-title":"Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel disease etiology and therapeutic target","volume":"87","author":"Janovick","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.phrs.2013.12.001_bib0095","doi-asserted-by":"crossref","first-page":"42198","DOI":"10.1074\/jbc.M510180200","article-title":"Mechanisms of cell-surface rerouting of an endoplasmic reticulum-retained mutant of the vasopressin V1b\/V3 receptor by a pharmacological chaperone","volume":"280","author":"Robert","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2013.12.001_bib0100","doi-asserted-by":"crossref","first-page":"19350","DOI":"10.1074\/jbc.M414043200","article-title":"Folding efficiency is rate-limiting in dopamine D4 receptor biogenesis","volume":"280","author":"Van Craenenbroeck","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2013.12.001_bib0105","doi-asserted-by":"crossref","first-page":"14604","DOI":"10.1074\/jbc.M511610200","article-title":"Pharmacological chaperone activity of SR49059 to functionally recover misfolded mutations of the vasopressin V1a receptor","volume":"281","author":"Hawtin","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2013.12.001_bib0110","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1124\/jpet.106.107987","article-title":"Ligands regulate cell surface level of the human \u03ba opioid receptor by activation-induced down-regulation and pharmacological chaperone-mediated enhancement: differential effects of nonpeptide and peptide agonists","volume":"319","author":"Chen","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.phrs.2013.12.001_bib0115","doi-asserted-by":"crossref","first-page":"8417","DOI":"10.1074\/jbc.M510601200","article-title":"Regulation of G protein-coupled receptor trafficking by inefficient plasma membrane expression: molecular basis of an evolved strategy","volume":"281","author":"Janovick","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2013.12.001_bib0120","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1124\/jpet.107.125500","article-title":"A select set of opioid ligands induce up-regulation by promoting the maturation and stability of the rat \u03ba-opioid receptor in human embryonic kidney 293 cells","volume":"323","author":"Wannemacher","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.phrs.2013.12.001_bib0125","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1600-0854.2008.00846.x","article-title":"Phe27Cys polymorphism alters the maturation and subcellular localization of the human \u03b4 opioid receptor","volume":"10","author":"Leskel\u00e4","year":"2009","journal-title":"Traffic"},{"key":"10.1016\/j.phrs.2013.12.001_bib0130","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1124\/mol.63.6.1256","article-title":"The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints","volume":"63","author":"Fredriksson","year":"2003","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.phrs.2013.12.001_bib0135","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1146\/annurev.pharmtox.40.1.389","article-title":"Molecular mechanisms and regulation of opioid receptor signaling","volume":"40","author":"Law","year":"2000","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.phrs.2013.12.001_bib0140","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1146\/annurev.biochem.73.011303.073940","article-title":"Opioid receptors","volume":"73","author":"Waldhoer","year":"2004","journal-title":"Annu Rev Biochem"},{"issue":"Suppl. 1","key":"10.1016\/j.phrs.2013.12.001_bib0145","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.neuropharm.2008.07.033","article-title":"Opioid receptors: from binding sites to visible molecules in vivo","volume":"56","author":"Kieffer","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2013.12.001_bib0150","doi-asserted-by":"crossref","first-page":"230","DOI":"10.2174\/138945012799201612","article-title":"Current research on opioid receptor function","volume":"13","author":"Feng","year":"2012","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.phrs.2013.12.001_bib0155","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.peptides.2013.10.001","article-title":"Endogenous opiates and behavior: 2012","volume":"50","author":"Bodnar","year":"2013","journal-title":"Peptides"},{"key":"10.1016\/j.phrs.2013.12.001_bib0160","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1124\/mol.112.083279","article-title":"Recent developments in the study of opioid receptors","volume":"83","author":"Cox","year":"2013","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.phrs.2013.12.001_bib0165","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0014-5793(94)80235-1","article-title":"ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization","volume":"341","author":"Mollereau","year":"1994","journal-title":"FEBS Lett"},{"key":"10.1016\/j.phrs.2013.12.001_bib0170","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/377532a0","article-title":"Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor","volume":"377","author":"Meunier","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2013.12.001_bib0175","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nature11111","article-title":"Structure of the \u03b4-opioid receptor bound to naltrindole","volume":"485","author":"Granier","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2013.12.001_bib0180","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature10954","article-title":"Crystal structure of the \u03bc-opioid receptor bound to a morphinan antagonist","volume":"485","author":"Manglik","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2013.12.001_bib0185","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nature11085","article-title":"Structure of the nociceptin\/orphanin FQ receptor in complex with a peptide mimetic","volume":"485","author":"Thompson","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2013.12.001_bib0190","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nature10939","article-title":"Structure of the human \u03ba-opioid receptor in complex with JDTic","volume":"485","author":"Wu","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2013.12.001_bib0195","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.tips.2009.11.008","article-title":"Receptor heteromerization and drug discovery","volume":"31","author":"Rozenfeld","year":"2010","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.phrs.2013.12.001_bib0200","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.coph.2009.09.007","article-title":"Opioid-receptor-heteromer-specific trafficking and pharmacology","volume":"10","author":"van Rijn","year":"2010","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.phrs.2013.12.001_bib0205","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1017\/erm.2012.5","article-title":"Opioid receptor heteromers in analgesia","volume":"14","author":"Costantino","year":"2012","journal-title":"Expert Rev Mol Med"},{"key":"10.1016\/j.phrs.2013.12.001_bib0210","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.tips.2005.04.001","article-title":"How individual sensitivity to opiates can be predicted by gene analyses","volume":"26","author":"Ikeda","year":"2005","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.phrs.2013.12.001_bib0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.fpc.0000182781.87932.0d","article-title":"Pharmacogenetics of opioid receptors and addiction","volume":"16","author":"Mayer","year":"2006","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.phrs.2013.12.001_bib0220","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/sj.clpt.6100095","article-title":"Pharmacogenetics of opioids","volume":"81","author":"Somogyi","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.phrs.2013.12.001_bib0225","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1146\/annurev.pharmtox.010909.105826","article-title":"Pharmacogenetics of drug dependence: role of gene variations in susceptibility and treatment","volume":"50","author":"Khokhar","year":"2010","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"October","key":"10.1016\/j.phrs.2013.12.001_bib0230","article-title":"Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females","author":"Clarke","year":"2013","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.phrs.2013.12.001_bib0235","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/humu.20638","article-title":"GPCR NaVa database: natural variants in human G protein-coupled receptors","volume":"29","author":"Kazius","year":"2008","journal-title":"Hum Mutat"},{"key":"10.1016\/j.phrs.2013.12.001_bib0240","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s004390000340","article-title":"Variant detection at the \u03b4 opioid receptor (OPRD1) locus and population genetics of a novel variant affecting protein sequence","volume":"107","author":"Gelernter","year":"2000","journal-title":"Hum Genet"},{"key":"10.1016\/j.phrs.2013.12.001_bib0245","doi-asserted-by":"crossref","first-page":"9608","DOI":"10.1073\/pnas.95.16.9608","article-title":"Single-nucleotide polymorphism in the human mu opioid receptor gene alters \u03b2-endorphin binding and activity: possible implications for opiate addiction","volume":"95","author":"Bond","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.phrs.2013.12.001_bib0250","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1471-4159.2007.04738.x","article-title":"The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor","volume":"103","author":"Kroslak","year":"2007","journal-title":"J Neurochem"},{"key":"10.1016\/j.phrs.2013.12.001_bib0255","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1042\/BJ20111050","article-title":"A common single nucleotide polymorphism A118G of the \u03bc opioid receptor alters its N-glycosylation and protein stability","volume":"441","author":"Huang","year":"2012","journal-title":"Biochem J"},{"key":"10.1016\/j.phrs.2013.12.001_bib0260","doi-asserted-by":"crossref","first-page":"13727","DOI":"10.1074\/jbc.275.18.13727","article-title":"Export from the endoplasmic reticulum represents the limiting step in the maturation and cell surface expression of the human \u03b4 opioid receptor","volume":"275","author":"Pet\u00e4j\u00e4-Repo","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2013.12.001_bib0265","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1074\/jbc.M007151200","article-title":"Newly synthesized human \u03b4 opioid receptors retained in the endoplasmic reticulum are retrotranslocated to the cytosol, deglycosylated, ubiquitinated, and degraded by the proteasome","volume":"276","author":"Pet\u00e4j\u00e4-Repo","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2013.12.001_bib0270","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1074\/jbc.M111.305656","article-title":"Cys27 variant of the human \u03b4 opioid receptor modulates maturation and cell surface delivery of Phe27 variant via heteromerization","volume":"287","author":"Leskel\u00e4","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2013.12.001_bib0275","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1124\/mol.64.1.32","article-title":"Rescuing the traffic-deficient mutants of rat \u03bc-opioid receptors with hydrophobic ligands","volume":"64","author":"Chaipatikul","year":"2003","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.phrs.2013.12.001_bib0280","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1124\/mol.110.064188","article-title":"The \u03bc-opioid receptor variant N190K is unresponsive to peptide agonists yet can be rescued by small-molecule drugs","volume":"78","author":"Fortin","year":"2010","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.phrs.2013.12.001_bib0285","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0304-3940(84)90475-0","article-title":"Up-regulation of opiate receptors by opiate antagonists in neuroblastoma-glioma cell culture: the possibility of interaction with guanosine triphosphate-binding proteins","volume":"50","author":"Barg","year":"1984","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.phrs.2013.12.001_bib0290","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S0022-3565(25)38093-6","article-title":"Mu opiate receptor down-regulation by morphine and up-regulation by naloxone in SH-SY5Y human neuroblastoma cells","volume":"265","author":"Zadina","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.phrs.2013.12.001_bib0295","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S0022-3565(25)22512-5","article-title":"Differential regulation of mu and delta opiate receptors by morphine, selective agonists and antagonists and differentiating agents in SH-SY5Y human neuroblastoma cells","volume":"270","author":"Zadina","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.phrs.2013.12.001_bib0300","doi-asserted-by":"crossref","first-page":"23171","DOI":"10.1074\/jbc.M610896200","article-title":"Opioid receptor pharmacological chaperones act by binding and stabilizing newly synthesized receptors in the endoplasmic reticulum","volume":"282","author":"Leskel\u00e4","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2013.12.001_bib0305","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1124\/mol.60.5.1064","article-title":"Inverse agonist up-regulates the constitutively active D3. 49(164)Q mutant of the rat \u03bc-opioid receptor by stabilizing the structure and blocking constitutive internalization and down-regulation","volume":"60","author":"Li","year":"2001","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.phrs.2013.12.001_bib0310","doi-asserted-by":"crossref","first-page":"47254","DOI":"10.1074\/jbc.M408154200","article-title":"Pharmacochaperones post-translationally enhance cell surface expression by increasing conformational stability of wild-type and mutant vasopressin V2 receptors","volume":"279","author":"W\u00fcller","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2013.12.001_bib0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/mol.112.080440","article-title":"\u03b2-Adrenergic agonists mediate enhancement of \u03b21-adrenergic receptor N-terminal cleavage and stabilization in vivo and in vitro","volume":"83","author":"Hakalahti","year":"2013","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.phrs.2013.12.001_bib0320","doi-asserted-by":"crossref","first-page":"35678","DOI":"10.1074\/jbc.M301888200","article-title":"Appropriate polarization following pharmacological rescue of V2 vasopressin receptors encoded by X-linked nephrogenic diabetes insipidus alleles involves a conformation of the receptor that also attains mature glycosylation","volume":"278","author":"Tan","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2013.12.001_bib0325","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1074\/jbc.272.5.2587","article-title":"Structural instability of a constitutively active G protein-coupled receptor. Agonist-independent activation due to conformational flexibility","volume":"272","author":"Gether","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2013.12.001_bib0330","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1073\/pnas.94.1.137","article-title":"Ligand-induced overexpression of a constitutively active \u03b22-adrenergic receptor: pharmacological creation of a phenotype in transgenic mice","volume":"94","author":"Samama","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.phrs.2013.12.001_bib0335","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0026-895X(24)26497-X","article-title":"The effect of mutations in the DRY motif on the constitutive activity and structural instability of the histamine H2 receptor","volume":"57","author":"Alewijnse","year":"2000","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.phrs.2013.12.001_bib0340","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1124\/mol.59.4.929","article-title":"The role of a conserved inter-transmembrane domain interface in regulating \u03b12a-adrenergic receptor conformational stability and cell-surface turnover","volume":"59","author":"Wilson","year":"2001","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.phrs.2013.12.001_bib0345","doi-asserted-by":"crossref","first-page":"12039","DOI":"10.1021\/bi0100945","article-title":"Constitutive activation of the \u03bc opioid receptor by mutation of D3.49(164), but not D3.32(147): D3.49(164) is critical for stabilization of the inactive form of the receptor and for its expression","volume":"40","author":"Li","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.phrs.2013.12.001_bib0350","doi-asserted-by":"crossref","first-page":"8829","DOI":"10.1021\/bi00152a020","article-title":"Thermodynamic measurements of the contributions of helix-connecting loops and of retinal to the stability of bacteriorhodopsin","volume":"31","author":"Kahn","year":"1992","journal-title":"Biochemistry"},{"key":"10.1016\/j.phrs.2013.12.001_bib0355","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1432-1033.1997.t01-2-00441.x","article-title":"Effect of nucleotides on the thermal stability and on the deuteration kinetics of the thermophilic F0F1 ATP synthase","volume":"244","author":"Villaverde","year":"1997","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.phrs.2013.12.001_bib0360","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1110\/ps.0240003","article-title":"Protein stability induced by ligand binding correlates with changes in protein flexibility","volume":"12","author":"Celej","year":"2003","journal-title":"Protein Sci"},{"key":"10.1016\/j.phrs.2013.12.001_bib0365","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.tips.2012.10.002","article-title":"Grand opening of structure-guided design for novel opioids","volume":"34","author":"Filizola","year":"2012","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.phrs.2013.12.001_bib0370","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1124\/jpet.102.048454","article-title":"Structure-activity relations of successful pharmacologic chaperones for rescue of naturally occurring and manufactured mutants of the gonadotropin-releasing hormone receptor","volume":"305","author":"Janovick","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.phrs.2013.12.001_bib0375","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1046\/j.1432-1327.2000.01457.x","article-title":"In vitro inhibition and intracellular enhancement of lysosomal \u03b1-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives","volume":"267","author":"Asano","year":"2000","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.phrs.2013.12.001_bib0380","doi-asserted-by":"crossref","first-page":"4989","DOI":"10.1074\/jbc.M107345200","article-title":"The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations","volume":"277","author":"Ficker","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2013.12.001_bib0385","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1146\/annurev.biochem.73.011303.073752","article-title":"Roles of N-linked glycans in the endoplasmic reticulum","volume":"73","author":"Helenius","year":"2004","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.phrs.2013.12.001_bib0390","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.tibs.2009.10.001","article-title":"N-glycan structures: recognition and processing in the ER","volume":"35","author":"Aebi","year":"2010","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.phrs.2013.12.001_bib0395","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1210\/endo.139.4.5881","article-title":"Association of gonadotropin receptor precursors with the protein folding chaperone calnexin","volume":"139","author":"Rozell","year":"1998","journal-title":"Endocrinology"},{"key":"10.1016\/j.phrs.2013.12.001_bib0400","doi-asserted-by":"crossref","first-page":"6766","DOI":"10.1021\/bi002699r","article-title":"Association of calnexin with wild type and mutant AVPR2 that causes nephrogenic diabetes insipidus","volume":"40","author":"Morello","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.phrs.2013.12.001_bib0405","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1034\/j.1600-0854.2003.00097.x","article-title":"Endoplasmic reticulum retention, degradation, and aggregation of olfactory G-protein coupled receptors","volume":"4","author":"Lu","year":"2003","journal-title":"Traffic"},{"key":"10.1016\/j.phrs.2013.12.001_bib0410","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.bbrc.2005.12.016","article-title":"Role of N-glycan-dependent quality control in the cell-surface expression of the AT1 receptor","volume":"340","author":"Lanct\u00f4t","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.phrs.2013.12.001_bib0415","doi-asserted-by":"crossref","first-page":"29086","DOI":"10.1074\/jbc.M801880200","article-title":"N-glycan-mediated quality control in the endoplasmic reticulum is required for the expression of correctly folded \u03b4-opioid receptors at the cell surface","volume":"283","author":"Markkanen","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2013.12.001_bib0420","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1124\/mol.108.054064","article-title":"\u03bc-Opioid receptor cell surface expression is regulated by its direct interaction with Ribophorin I","volume":"75","author":"Ge","year":"2009","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.phrs.2013.12.001_bib0425","doi-asserted-by":"crossref","first-page":"33333","DOI":"10.1074\/jbc.M109.043364","article-title":"Calnexin improves the folding efficiency of mutant rhodopsin in the presence of pharmacological chaperone 11-cis-retinal","volume":"284","author":"Noorwez","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2013.12.001_bib0430","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1083\/jcb.109.1.61","article-title":"Brefeldin A redistributes resident and itinerant Golgi proteins to the endoplasmic reticulum","volume":"109","author":"Doms","year":"1989","journal-title":"J Cell Biol"},{"key":"10.1016\/j.phrs.2013.12.001_bib0435","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1242\/jcs.115.14.2907","article-title":"The cellular fate of mutant rhodopsin: quality control, degradation and aggresome formation","volume":"115","author":"Saliba","year":"2002","journal-title":"J Cell Sci"},{"key":"10.1016\/j.phrs.2013.12.001_bib0440","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1210\/me.2003-0073","article-title":"Thyrotropin-releasing hormone receptor processing: role of ubiquitination and proteasomal degradation","volume":"17","author":"Cook","year":"2003","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.phrs.2013.12.001_bib0445","doi-asserted-by":"crossref","first-page":"11610","DOI":"10.1074\/jbc.M513552200","article-title":"Calcium-sensing receptor ubiquitination and degradation mediated by the E3 ubiquitin ligase dorfin","volume":"281","author":"Huang","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2013.12.001_bib0450","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1124\/mol.107.040931","article-title":"Derlin-1 and p97\/valosin-containing protein mediate the endoplasmic reticulum-associated degradation of human V2 vasopressin receptors","volume":"73","author":"Schwieger","year":"2008","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.phrs.2013.12.001_bib0455","doi-asserted-by":"crossref","first-page":"34897","DOI":"10.1074\/jbc.M113.514745","article-title":"Endoplasmic reticulum associated degradation (ERAD) controls cell surface expression of GABAB receptors","volume":"288","author":"Zemoura","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.phrs.2013.12.001_bib0460","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1016\/0024-3205(74)90135-0","article-title":"Binding of 3H-naloxone in the mouse brain: effect of ions and tolerance development","volume":"14","author":"Hitzemann","year":"1974","journal-title":"Life Sci"},{"key":"10.1016\/j.phrs.2013.12.001_bib0465","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0022-3565(25)20595-X","article-title":"Neurochemical and functional correlates of naltrexone-induced opiate receptor up-regulation","volume":"232","author":"Tempel","year":"1985","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.phrs.2013.12.001_bib0470","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S0022-3565(25)13426-5","article-title":"Antagonist-induced opioid receptor up-regulation. II. Regionally specific modulation of mu, delta and kappa binding sites in rat brain revealed by quantitative autoradiography","volume":"247","author":"Morris","year":"1988","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.phrs.2013.12.001_bib0475","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/0024-3205(88)90587-5","article-title":"Upregulation of opioid receptor subtypes correlates with potency changes of morphine and DADLE","volume":"43","author":"Yoburn","year":"1988","journal-title":"Life Sci"},{"key":"10.1016\/j.phrs.2013.12.001_bib0480","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0026-895X(25)13131-3","article-title":"Differential down- and up-regulation of rat brain opioid receptor types and subtypes by buprenorphine","volume":"44","author":"Belcheva","year":"1993","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.phrs.2013.12.001_bib0485","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0014-2999(97)01584-7","article-title":"Chronic naltrexone differentially affects supraspinal \u03b4-opioid receptor-mediated antinociception","volume":"345","author":"Kest","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.phrs.2013.12.001_bib0490","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S0306-4522(97)00659-3","article-title":"Quantitative immunolocalization of mu opioid receptors: regulation by naltrexone","volume":"85","author":"Unterwald","year":"1998","journal-title":"Neuroscience"},{"key":"10.1016\/j.phrs.2013.12.001_bib0495","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1046\/j.1460-9568.2003.02502.x","article-title":"Receptor-selective changes in \u03bc-, \u03b4- and \u03ba-opioid receptors after chronic naltrexone treatment in mice","volume":"17","author":"Lesscher","year":"2003","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.phrs.2013.12.001_bib0500","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1124\/jpet.107.127019","article-title":"\u03bc-opioid receptor up-regulation and functional supersensitivity are independent of antagonist efficacy","volume":"323","author":"Sirohi","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.phrs.2013.12.001_bib0505","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1210\/me.2006-0066","article-title":"Protein folding as posttranslational regulation: evolution of a mechanism for controlled plasma membrane expression of a G protein-coupled receptor","volume":"20","author":"Conn","year":"2006","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.phrs.2013.12.001_bib0510","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0006-8993(95)00615-W","article-title":"Assessment of delta opioid antinociception and receptor mRNA levels in mouse after chronic naltrexone treatment","volume":"691","author":"Jenab","year":"1995","journal-title":"Brain Res"},{"key":"10.1016\/j.phrs.2013.12.001_bib0515","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0169-328X(95)00143-G","article-title":"Chronic opioid antagonist administration upregulates mu opioid receptor binding without altering mu opioid receptor mRNA levels","volume":"33","author":"Unterwald","year":"1995","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.phrs.2013.12.001_bib0520","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0169-328X(96)00305-1","article-title":"Chronic morphine and naltrexone fail to modify mu-opioid receptor mRNA levels in the rat brain","volume":"45","author":"Castelli","year":"1997","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.phrs.2013.12.001_bib0525","doi-asserted-by":"crossref","first-page":"6542","DOI":"10.1021\/jm4004335","article-title":"Class A G-protein-coupled receptor (GPCR) dimers and bivalent ligands","volume":"56","author":"Hiller","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.phrs.2013.12.001_bib0530","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1124\/mol.104.010272","article-title":"Opioid receptor homo- and heterodimerization in living cells by quantitative bioluminescence resonance energy transfer","volume":"67","author":"Wang","year":"2005","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.phrs.2013.12.001_bib0535","doi-asserted-by":"crossref","first-page":"12997","DOI":"10.1021\/bi701436w","article-title":"Trafficking of preassembled opioid \u03bc-\u03b4 heterooligomer-Gz signaling complexes to the plasma membrane: coregulation by agonists","volume":"46","author":"Hasbi","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.phrs.2013.12.001_bib0540","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2210-3-14","article-title":"Enhanced spontaneous activity of the mu opioid receptor by cysteine mutations: characterization of a tool for inverse agonist screening","volume":"3","author":"Brillet","year":"2003","journal-title":"BMC Pharmacol"},{"key":"10.1016\/j.phrs.2013.12.001_bib0545","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0022-3565(24)35398-4","article-title":"Ligand-induced changes in surface \u03bc-opioid receptor number: relationship to G protein activation","volume":"292","author":"Zaki","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.phrs.2013.12.001_bib0550","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0022-3565(24)29470-2","article-title":"Agonist-, antagonist-, and inverse agonist-regulated trafficking of the \u03b4-opioid receptor correlates with, but does not require, G protein activation","volume":"298","author":"Zaki","year":"2001","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661813002685?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661813002685?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T06:04:56Z","timestamp":1746079496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661813002685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":110,"alternative-id":["S1043661813002685"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2013.12.001","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting opioid receptors with pharmacological chaperones","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2013.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}